Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Original versus generic rivaroxaban resemblance study
TCTR20240606003Phase 4Unknown
- Sponsor
- Chiang Mai University
- Start
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of rivaroxaban in Atrial fibrillation (AFib), sponsored by Chiang Mai University. Primary endpoint: Anti-factor Xa activity. Status: unknown.
02
Drugs
rivaroxaban
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on TCTR20240606003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20240606003.